Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Cough, Nasal congestion, SARS-CoV-2 test
Clinical narrative: dry cough; Nasal Congestion; Tested positive on May 2 and started Paxlovid treatment almost immediately before having symptoms; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Tested positive on May 2 and started Paxlovid treatment almost immediately before having symptoms), COUGH (dry cough) and NASAL CONGESTION (Nasal Congestion) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939909) for COVID-19 vaccination.     No Medical History information was reported.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-May-2022, the patient experienced COVID-19 (Tested positive on May 2 and started Paxlovid treatment almost immediately before having symptoms). On 12-May-2022, the patient experienced COUGH (dry cough) and NASAL CONGESTION (Nasal Congestion). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 02-May-2022 to 06-May-2022 for COVID-19 treatment, at a dose of 1 UNK. At the time of the report, COVID-19 (Tested positive on May 2 and started Paxlovid treatment almost immediately before having symptoms) outcome was unknown and COUGH (dry cough) and NASAL CONGESTION (Nasal Congestion) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 02-May-2022, SARS-CoV-2 test: positive (Positive) Tested positive on May 2. On 06-May-2022, SARS-CoV-2 test: negative (Negative) Tested negative for COVID 19 on May. On 15-May-2022, SARS-CoV-2 test: positive (Positive) got another positive test result on May 15.         No concomitant drug reported. Patient started Paxlovid treatment almost immediately before having symptoms. Patient reported some symptoms began on12 or 3 May, like dry cough with nasal congestion starting on 14 May but thought there was no way it could be COVID with symptoms progressing though remaining very mild. Patient took a test out of curiosity and get another positive test result on 15 May.  Company comment: This spontaneous case concerns a 35-year-old male patient, with no reported medical history, who experienced unexpected, non-serious, AESI of COVID-19, approximately 7 months after receiving mRNA-1273 vaccine as a third dose.  Dose 1 and Dose 2 were given with a 28-day interval.  The patient was treated with Nirmatrelvir-Ritonavir (Paxlovid) for 5 days on unknown dose and frequency, before having symptoms.  4 days after the onset of the event, the patient tested negative for SARS-CoV-2 test.  Around 10 days after the onset of the event, the patient noted onset of dry cough with nasal congestion.  On the 14th day after the onset of the event, the patient tested positive again on SARS-CoV-2 test.   The outcome of the event was unknown.  The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 35-year-old male patient, with no reported medical history, who experienced unexpected, non-serious, AESI of COVID-19, approximately 7 months after receiving mRNA-1273 vaccine as a third dose.  Dose 1 and Dose 2 were given with a 28-day interval.  The patient was treated with Nirmatrelvir-Ritonavir (Paxlovid) for 5 days on unknown dose and frequency, before having symptoms.  4 days after the onset of the event, the patient tested negative for SARS-CoV-2 test.  Around 10 days after the onset of the event, the patient noted onset of dry cough with nasal congestion.  On the 14th day after the onset of the event, the patient tested positive again on SARS-CoV-2 test.   The outcome of the event was unknown.  The benefit-risk relationship of mRNA-1273 is not affected by this report.